Editorial Board — Medscape Oncology

Board Members

  • Harold J. Burstein, MD, PhD
    • Harvard Medical School
      Dana-Farber Cancer Institute
      Boston, Massachusetts
  • Bruce D. Cheson, MD
    • Georgetown University
      Georgetown University Hospital
      Washington, DC
  • Avraham Eisbruch, MD
    • Clinical Research University of Michigan Medical School and Medical Center
      Ann Arbor, Michigan
  • David J. Kerr, MD
    • University of Oxford
      Oxford Radcliffe Hospitals Trust
      Oxford, United Kingdom
  • Mark G. Kris, MD
    • Memorial Sloan-Kettering Cancer Center
      Weill Cornell Medical College
      New York, New York
  • Corey J. Langer, MD
    • University of Pennsylvania Medical School
      Abramson Cancer Center
      Philadelphia, Pennsylvania
  • Maurie Markman, MD
    • Cancer Treatment Centers of America
      Philadelphia, Pennsylvania
 

Board Member Details

Harold J. Burstein, MD, PhD
Harold J. Burstein, MD, PhD

Associate Professor, Harvard Medical School; Medical Oncologist, Dana-Farber Cancer Institute, Boston, Massachusetts

Harold J. Burstein, MD, PhD, has disclosed no relevant financial relationships.

Bruce D. Cheson, MD
Bruce D. Cheson, MD

Professor of Medicine, Department of Hematology-Oncology; Deputy Chief, Hematology-Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC

Bruce D. Cheson, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Celgene; Astellas; Pharmacyclics; Gilead; Roche-Genentech; AbbVie

Avraham Eisbruch, MD
Avraham Eisbruch, MD

Professor, University of Michigan; Associate Chair, University of Michigan Hospital, Ann Arbor, Michigan

Avraham Eisbruch, MD, has disclosed the following relevant financial relationships:
Received research grant from: National Institutes of Health (RO1)

David J. Kerr, CBE, MD, DSc, FRCP, FMedSci
David J. Kerr, MD

Professor, Nuffield Department of Clinical Laboratory Science, University of Oxford; Professor of Cancer Medicine, Oxford Cancer Centre, Oxford, United Kingdom

David Kerr, CBE, MD, DSc, FRCP, FMedSci, has disclosed the following relevant financial relationships:
Served as a director, officer, partner, employee, advisor, consultant, or trustee for: Celleron ; Oxford Cancer Biomarkers
Serve(d) as a speaker or a member of a speakers bureau for: Merck-Serono
Received research grant from: Roche
Have a 5% or greater equity interest in: Celleron Therapeutics; Oxford Cancer Biomarkers
Received income in an amount equal to or greater than $250 from: Oxford Cancer Biomarkers

Mark G. Kris, MD
Mark G. Kris, MD

Professor of Medicine, Weill Cornell Medical College; Attending Physician, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York

Mark Kris, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AstraZeneca; Roche/Genentech; Ariad Pharmaceuticals
Received a research grant from: Pfizer Inc; PUMA; Roche/Genentech

,
Corey J. Langer, MD
Corey J. Langer, MD

Professor of Medicine, University of Pennsylvania Medical School; Director, Thoracic Oncology, Abramson Cancer Center, Philadelphia, Pennsylvania

Corey J. Langer, MD, has disclosed the following relevant financial relationships:
Received institutional grant/research support from: Bristol-Myers Squibb Company; Pfizer Inc; Eli Lilly and Company; Genentech, Inc.; OSI Pharmaceuticals, Inc.; Merck & Co. Inc; GlaxoSmithKline; Nektar; Clovis Oncology
Served as a scientific advisor for: Bristol-Myers Squibb Company; ImClone Systems Incorporated; sanofi-aventis; Pfizer Inc; Eli Lilly and Company; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals Corporation; Genentech, Inc.; Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals, Inc.; Abbott Laboratories; Morphobiotek, Inc.; Biodesix; Clariant; CarisDx; Vertex; Synta Pharmaceuticals Corp.; Celegene; Boehringer Ingelheim Pharmaceuticals, Inc.; AbbVie; Clovis Oncology; Merck & Co. Inc
Served as a speaker or a member of a speakers bureau for: Eli Lilly and Company; OSI Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; ImClone Systems Incorporated (all curtailed as of 12/10)
Data Safety Monitoring Committee Member: Eli Lilly and Company; Amgen Inc; Synta Pharmaceuticals Corp.; Agennix; Peregrine; SWOG; Incyte Corporation
CME: Imedex; Physicians Education Resource; TRM Oncology

Maurie Markman, MD
Maurie Markman, MD

Clinical Professor, Drexel University College of Medicine; President, Medical & Science, Cancer Treatment Centers of America, Philadelphia, Pennsylvania

Maurie Markman, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Celgene; Crititech; Amgen Inc.
Serve(d) as a speaker or a member of a speakers bureau for: Genentech, Inc; AstraZeneca Pharmaceuticals LP Received income in an amount equal to or greater than $250 from: Genentech, Inc; AstraZeneca
Pharmaceuticals LP; Celgene; Crititech; Amgen Inc.

John L. Marshall, MD
John L. Marshall, MD

Professor of Medicine; Chief, Division of Hematology-Oncology; Director, Clinical Research, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

John L. Marshall, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Genentech, Inc; Amgen Inc; Bayer HealthCare Pharmaceuticals; Celgene Corporation
Serve(d) as a speaker or member of a speakers bureau for: Genentech, Inc; Amgen Inc; Bayer HealthCare Pharmaceuticals; Celgene Corporation
Received research grant from: Genentech, Inc; Amgen Inc; Bayer HealthCare Pharmaceuticals; Celgene Corporation
Received income in an amount equal to or greater than $250 from: Genentech, Inc; Amgen Inc; Bayer HealthCare Pharmaceuticals; Celgene Corporation

Kathy D. Miller, MD
Kathy D. Miller, MD

Professor, Department of Medicine (Hematology-Oncology), Indiana University Simon Cancer Center; Co-Director, Breast Cancer Program, Indiana University Simon Cancer Center, Indianapolis, Indiana

Kathy D. Miller, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Clovis; Incyte; Tesaro

,
Howard M. Sandler, MD
Howard M. Sandler, MD

Professor, Department of Radiation Oncology; Chairman, Cedars-Sinai Medical Center, Los Angeles, California

Howard M. Sandler, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Ortho-McNeil-Janssen Pharmaceuticals, Inc; sanofi-aventis; eviti; Ferring; Clovis Oncology; Blue Earth Diagnostics

Richard M. Stone, MD
Richard M. Stone, MD

Professor of Medicine, Harvard Medical School; Director, Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, Massachusetts

Richard M. Stone, MD, has disclosed the following relevant financial relationships:
Received research grant from: Novartis Pharmaceuticals Corporation
Received income in an amount equal to or greater than $250 from: Amgen Inc; Abbvie; Roche; Seattle Genetics, Inc; Bristol-Myers Squibb Company; Celator

Nicholas J. Vogelzang, MD
Nicholas J. Vogelzang, MD

Research Medical Director, US Oncology Research, Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada

Nicholas J. Vogelzang, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Amgen Inc.; Janssen Biotech, Inc; BIND Biosciences; AVEO
Serve(d) as a speaker or a member of a speakers bureau for: Dendreon Corporation; Bayer HealthCare Pharmaceuticals; Medivation, Inc.; Caris Molecular Profiling Institute; Millennium Pharmaceuticals, Inc; sanofi-aventis; GlaxoSmithKline
Received honoraria from: DAVA Oncology; Mannkind; UpToDate; Abbvie; Bavarian Nordic; Endocyte Stock: Caris Life Sciences
Received research funding from: PAREXEL International; Progenics Pharmaceuticals, Inc; Exelixis; US Oncology; Viamet Pharmaceuticals; Endocyte; GlaxoSmithKline
Received travel, accommodations, or expenses from: Genentech/Roche; Celgene; US Oncology; Dendreon; Novartis Pharmaceuticals Corporation; Pfizer Inc; Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals, Inc.; Exelixis

Louis M. Weiner, MD
Louis M. Weiner, MD

Professor, Department of Oncology, Georgetown University Medical Center; Director, Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC

Louis M. Weiner, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie Pharmaceuticals; Genentech Inc; Merck & Co Inc; Novartis
Pharmaceuticals; Celldex Pharmaceuticals; Jounce Pharmaceuticals; Merrimack Pharmaceuticals; Cytomx
Investment: Targeted Diagnostics and Therapeutics, Inc.

John R. Wingard, MD
John R. Wingard, MD

Professor of Medicine, University of Florida; Director, Bone Marrow Transplant Program, Shands Hospital at the University of Florida Health, Gainesville, Florida

John R. Wingard, MD, has disclosed the following relevant financial relationships:
Serve(d) as a speaker or member of a speakers bureau for: Pfizer Inc.
Received consultant fees from: Astellas Pharma, Inc.; Merck & Co., Inc.; Gilead Sciences, Inc.; Vical